Abstract
Clear recommendations for the management of acute varicella-zoster virus (VZV) infections for cases of significant exposure and the use of prophylactic drugs after solid-organ transplantation are missing due to the lack of evidence by prospective studies. Heterogeneity in patient groups, patient numbers, age groups, immunosuppressive regimens, timing, and dosage of aciclovir and/or varicella-zoster immunoglobulin (VZIG), pre-transplant vaccination or VZV wild-type infection and inconsistency of data make comparability of different studies impossible. Although the benefit of aciclovir and/or VZIG is uncertain in immunosuppressed children, prospective controlled double-blind studies are not feasible for ethical considerations as fatal cases with disseminating varicella disease are well known in these patient groups despite the use of aciclovir and/or VZIG, whereas severe side-effects of these drugs are rare. However, a reporting bias is likely as mainly severe or fatal cases might have been predominantly published or cases of successfully used aciclovir and/or VZIG in mild cases or in cases of breakthrough infections after vaccination. As neither VZIG prophylaxis nor treatment with intravenous aciclovir offers complete protection against severe VZV infection to immunosuppressed pediatric solid-organ transplant recipients, high priority should be given to vaccination against VZV prior to transplantation, and, most importantly, in their close contact persons. Clinical observations suggest that only assessment of humoral immunity together with cellular immunity may allow predication about protection in exposed patients.
Similar content being viewed by others
Explore related subjects
Discover the latest articles and news from researchers in related subjects, suggested using machine learning.References
Slifkin M, Doron S, Snydham DR (2004) Viral prophylaxis in organ transplant patients. Drugs 64:2763–2792
Heininger U, Seward JF (2006) Varicella. Lancet 368:1365–1376
Lynfield R, Herrin JT, Rubin RH (1992) Varicella in pediatric renal-transplant recipients. Pediatrics 90:216–220
Sauerbrei A, Farber I, Brandstadt A, Schake M, Wutzler P (2004) Immunofluorescence test for sensitive detection of varicella-zoster virus-specific IgG: an alternative to fluorescent antibody to membrane antigen test. J Virol Methods 119:25–30
White CJ, Kuter BJ, Ngai A, Hildebrand CS, Isganitis KL, Patterson CM, Capra A, Miller WJ, Krah DL, Provost PJ (1992) Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody disease. Pediatr Infect Dis J 11:19–23
Li S, Chan IS, Matthews H, Heyse JF, Chan CY, Kuter BJ, Kaplan KM, Vessey SJ, Sadoff JC (2002) Inverse relationship between six-week postvaccination varicella antibody response to vaccine and likelihood of long-term breakthrough infection. Pediatr Infect Dis J 21:338–342
Feldhoff CM, Balfour HH, Simmons RL, Najarian JS, Maurer SM (1981) Varicella in children with renal transplants. J Pediatr 98:25–31
Rothwell WS, Gloor JM, Morgenstern BZ, Milliner DS (1999) Disseminated varicella infection in pediatric renal transplant recipients treated with mycophenolate mofetil. Transplantation 68:158–161
Laube GF, Berger C, Goetschel P, Leumann E, Neuhaus TJ (2002) Immunization in children with chronic renal failure. Pediatr Nephrol 17:638–642
Breuer J, Schmid DS, Gerson AA (2008) Use and limitations of varicella-zoster virus-specific serological testing to evaluate breakthrough disease in vaccinees and to screen for susceptibility to varicella. J Infect Dis 197:S147–S151
Feldman S, Hughes WT, Daniel CB (1975) Varicella in children with cancer: seventy-seven cases. Pediatrics 56:388–397
Izurieta HS, Strebel PM, Blake PA (1997) Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center. JAMA 278:1495–1499
Smith JG, Liu X, Kaufhold RM, Clair J, Caulfield MJ (2001) Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus. Clin Diagn Lab Immunol 8:871–879
Vossen MT, Gent MR, Weel JF, de Jong MD, van Lier RA, Kuijpers TW (2004) Development of virus-specific CD4+ T cells on reexposure to varicella-zoster virus. J Infect Dis 190:72–82
Weinberg A, Horslen SP, Kaufman SS, Jesser R, Devoll-Zabrocki A, Fleckten BL, Kochanowicz S, Seipel KR, Levin MJ (2006) Safety and immunogenicity of varicella-zoster virus vaccine in pediatric liver and intestine transplant recipients. Am J Transplant 6:565–568
Starko KM, Ray CG, Dominguez LB, Stromberg WL, Woodall DF (1980) Reyes syndrome and salicylate use. Pediatrics 66:859–864
Lesko SM, O'Brien KL, Schwartz B, Vezina R, Mitchell AA (2001) Invasive group A streptococcal infection and nonsteroidal antiinflammatory drug use among children with primary varicella. Pediatrics 107:1108–1115
Zerr DM, Alexander ER, Duchin JS, Koutsky LA, Rubens CE (1999) A case-control study of necrotizing fasciitis during primary varicella. Pediatrics 103:783–790
Academy of Pediatrics Committee on Infectious Diseases (1993) The use of oral aciclovir in otherwise healthy children with varicella. Pediatrics 91:858
Balfour HH, Kelly JM, Suarez CS, Heussner RC, Englund JA, Crane DD, McGuirt PV, Clemmer AF, Aeppli DM (1990) Aciclovir treatment of varicella in otherwise healthy children. J Pediatr 116:633–639
Enright AM, Prober CG (2003) Antiviral therapy in children with varicella zoster virus and herpes simplex virus infections. Herpes 10:32–37
Shepp DH, Dandliker PS, Meyers JD (1986) Treatment of varicella zoster virus-infection in severely immunocompromised patients - A randomized comparison of aciclovir and vidarabine. N Engl J Med 314:208–212
Fishman JA, Rubin RH (1998) Infection in organ-transplant recipients - Reply. N Engl J Med 339:1246
Zeng L, Nath CE, Blair EY, Shaw PJ, Stephen K, Earl JW, Coakley JC, McLAchlan AJ (2009) Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir. Antimicrob Agents Chemother 53:2918–2927
Brigden D, Bye A, Fowle AS, Rogers H (1981) Human pharmacokinetics of acyclovir (an antiviral agent) following rapid intravenous injection. J Antimicrob Chemother 7:399–404
Dunkle LM, Arvin AM, Whitley RJ, Rotbart HA, Feder HM Jr, Feldman S, Gershon AA, Levy ML, Hayden GF, McGuirt PV (1991) A controlled trial of aciclovir for chickenpox in normal children. N Engl J Med 325:1539–1544
Yoshikawa T, Suga S, Kozawa T, Kawaguchi S, Asano Y (1998) Persistence of protective immunity after postexposure prophylaxis of varicella with oral aciclovir in the family setting. Arch Dis Child 78:61–63
Huang YC, Lin TY, Chiu CH (1995) Aciclovir prophylaxis of varicella after household exposure. Pediatr Infect Dis J 14:152–154
Asano Y, Yoshikawa T, Suga S, Kobayashi I, Nakashima T, Yazaki T, Ozaki T, Yamada A, Imanishi J (1993) Postexposure prophylaxis of varicella in family contact by oral aciclovir. Pediatrics 92:219–222
Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ (1995) Valaciclovir compared with aciclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 39:1546–1553
Faulds D, Heel RC (1990) Ganciclovir - A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs 39:597–638
McGregor RS, Zitelli BJ, Urbach AH, Malatack JJ, Gartner JC (1989) Varicella in pediatric orthotopic liver-transplant recipients. Pediatrics 83:256–261
Van Der Zwet EC, Vandenbroucke-Grauls CM, van Elburg RM, Cranedonk A, Zaaijer HL (2002) Neonatal antibody titers against varicella-zoster virus in relation to gestational age, birth weight, and maternal titer. Pediatrics 109:79–85
Zaia JA, Levin MJ, Preblud SR, Leszczynski J, Wright GG, Ellis RJ, Curtis AC, Valerio MA, LeGore J (1983) Evaluation of varicella-zoster immune globulin - protection of immunosuppressed children after household exposure to varicella. J Infect Dis 147:737–743
Arbeter AM, Granowetter L, Starr SE, Lange B, Wimmer R, Plotkin SA (1990) Immunization of children with acute lymphoblastic-leukemia with live attenuated varicella vaccine without complete suspension of chemotherapy. Pediatrics 85:338–344
Brunell PA, Shehab Z, Geiser C, Waugh JE (1982) Administration of live varicella vaccine to children with leukemia. Lancet 2:1069–1073
Levin MJ, Gershon AA, Weinberg A, Blanchard S, Nowak B, Palumbo B, Chan CY (2001) Immunization of HIV-infected children with varicella vaccine. J Pediatr 139:305–310
Rivest P, Bedard L, Valiquette L, Mills E, Lebel MH, Lavoie G, Carsley J (2001) Severe complications associated with varicella: province of Quebec, April 1994 to March 1996. Can J Infect Dis 12:21–26
Ljungman P, Lönnqvist B, Ringdén O, Skinhöj P, Gahrton G (1989) A randomized trial of oral versus intravenous aciclovir for treatment of herpes zoster in bone marrow transplant recipients. Nordic Bone Marrow Transplant Group. Bone Marrow Transplant 4:613–615
Kashtan CE, Cook M, Chavers BM, Mauer SM, Nevins TE (1997) Outcome of chickenpox in 66 pediatric renal transplant recipients. J Pediatr 131:874–877
Broyer M, Tete MJ, Guest G, Gagnadoux MF, Rouzioux C (1997) Varicella and zoster in children after kidney transplantation: long-term results of vaccination. Pediatrics 99:35–39
Lauzurica R, Bayes B, Frias C, Fontseré N, Hernandez A, Matas L, Jimenez A, Bonet J, Romero R (2003) Disseminated varicella infection in adult renal allograft recipients: Role of mycophenolate mofetil. Transplant Proc 35:1758–1759
Jose MD, Roake JA, Robson RA (2000) The role of mycophenolate mofetil in chickenpox after renal transplantation. Transplantation 70:242–243
Hayes K, Shakuntala V, Pingle A, Dhawan IK, Masri MA (1992) Safe use of aciclovir (Zovirax) in renal-transplant patients on cyclosporine-A therapy – case reports. Transplant Proc 24:1926
Fehr T, Bossart W, Wahl C, Binswanger U (2002) Disseminated varicella infection in adult renal allograft recipients: four cases and a review of the literature. Transplantation 73:608–611
Boeckh M, Kim HW, Flowers MED, Meyers JD, Bowden RA (2006) Long-term aciclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation—a randomized double-blind placebo-controlled study. Blood 107:1800–1805
Asano-Mori Y, Kanda Y, Oshima K, Kako S, Shinohara A, Nakasone H, Sato H, Watanabe T, Hosoya N, Izutsu K, Asai T, Hangaishi A, Motokura T, Chiba S, Kurokawa M (2008) Long-term ultra-low-dose aciclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Am J Hematol 83:472–476
Kim DH, Kumar D, Messner HA, Minden M, Gupta V, Kuruvilla J, Chae YS, Sohn SK, Lipton JH (2008) Clinical efficacy of prophylactic strategy of long-term low-dose aciclovir for varicella-zoster virus infection after allogeneic peripheral blood stem cell transplantation. Clin Transplant 22:770–779
Aitken C, Hawrami K, Miller C, Muir WB, Yaqoob M, Breuer J (1999) Simultaneous treatment of cytomegalovirus and varicella zoster infections in a renal transplant recipient with ganciclovir: use of viral load to monitor response to treatment. J Med Virol 59:412–414
Steer CB, Szer J, Sasadeusz J, Matthews JP, Beresford JA, Grigg A (2000) Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir. Bone Marrow Transplant 25:657–664
Dodd DA, Burger J, Edwards KM, Dummer JS (2001) Varicella in a pediatric heart transplant population on nonsteroid maintenance immunosuppression. Pediatrics 108:e80
Goldstein SL, Somers MJG, Lande MB, Brewer ED, Jabs KL (2000) Aciclovir prophylaxis of varicella in children with renal disease receiving steroids. Pediatr Nephrol 14:305–308
Gershon A, Brunell PA, Claps AA, Doyle EF (1972) Steroid-therapy and varicella. J Pediatr 81:1034
Kasper WJ, Howe PM (1990) Fatal varicella after a single course of corticosteroids. Pediatr Infect Dis J 9:729–732
Harmon WE (1991) Opportunistic infections in children following renal-transplantation. Pediatr Nephrol 5:118–125
Melzi ML, Sonzogni A, Comoli P, Stroppa P, Riva S, Altobelli M, Casati A, Torre G, Alberti D, Guizzetti M, Furione M, Spada M, Colledan M, Gridelli B (2006) Specific autologous cytotoxic T lymphocytes for chronic varicella in a liver transplanted child. Pediatr Transplant 10:240–243
Gershon AA, LaRussa P, Hardy I, Steinberg S, Silverstein S (1992) Varicella vaccine—the American experience. J Infect Dis 166:S63–S68
Krause PR, Klinman DM (1995) Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine. J Pediatr 127:518–525
Rodriguez-Moreno A, Sanchez-Fructuoso AI, Calvo N, Ridao N, Conesa J, Marquez M, Prats D, Barrientos A (2006) Varicella infection in adult renal allograft recipients: experience at one center. Transplant Proc 38:2416–2418
Errasti P, Alvarez ML, Gomez G, Lavilla FJ, Garcia N, Ballester B, García I, Purroy A (1999) Chickenpox in four adult renal transplant recipients. Transplant Proc 31:2341–2342
Shahbazian H, Ehsanpour A (2007) An outbreak of chickenpox in adult renal transplant recipients. Exp Clin Transplant 5:604–606
Robertson S, Newbigging K, Carman W, Jones G, Isles C (2006) Fulminating varicella despite prophylactic immune globulin and intravenous aciclovir in a renal transplant recipient: should renal patients be vaccinated against VZV before transplantation? Clin Transplant 20:136–138
Ishikawa N, Tanabe K, Shimmura H, Tokumoto T, Toma H (2000) Primary varicella virus in adult renal transplant recipients: case reports. Transplant Proc 32:1952–1953
Levitsky J, Te HS, Faust TW, Cohen SM (2002) Varicella infection following varicella vaccination in a liver transplant recipient. Am J Transplant 2:880–882
Pacini-Edelstein SJ, Mehra M, Ament ME, Vargas JH, Martin MG, McDiarmid TV (2003) Varicella in pediatric liver transplant patients: a retrospective analysis of treatment and outcome. J Pediatr Gastroenterol Nutr 37:183–186
Levitsky J, Kalil AC, Meza JL, Hurst GE, Freifeld A (2005) Chicken pox after pediatric liver transplantation. Liver Transplant 11:1563–1566
Donati M, Zuckerman M, Dhawan A, Hadzic N, Heaton N, North-Lewis P, Mieli-Vergani G (2000) Response to varicella immunization in pediatric liver transplant recipients. Transplantation 70:1401–1404
Carby M, Jones A, Burke M, Hall A, Banner N (2007) Varicella infection after heart and lung transplantation: a single-center experience. J Heart Lung Transplant 26:399–402
Cabezón Ruiz SC, Cisneros JM, Lage Galle EL, Ordónez A, Hinojosa RF, Moràn Risco JE, Hernández A (2003) Characteristics and repercussion of varicella-zoster virus infection in cardiac transplant. Transplant Proc 35:2004–2005
Vossen MTM, Gent MR, Weel JFL, de Jong MD, van Lier RAW, Kuijpers TW (2004) Development of virus-specific CD4+ T cells on reexposure to varicella-zoster virus. J Infect Dis 190:72–82
Watson B, Rothstein E, Bernstein H, Arbeter A, Arvin A, Chartrand S, Clements D, Kumar ML, Reisinger K, Blatter M, Starr SE, Staehle B, Ngai A, White CJ (1995) Safety and cellular and humoral immune responses of a booster dose of varicella vaccine 6 years after primary immunization. J Infect Dis 172:217–219
Zerboni L, Nader S, Aoki K, Arvin AM (1998) Analysis of the persistence of humoral and cellular immunity in children and adults immunized with varicella vaccine. J Infect Dis 177:1701–1704
Watson B (2008) Humoral and cell-mediated immune responses in children and adults after 1 and 2 doses of varicella. J Infect Dis 197:S143–S146
Weinberg A, Levin MJ (2010) VZV T cell-mediated immunity. Curr Top Microbiol Immunol 342:341–357
Prelog M, Zimmerhackl LB (2010) Varicella vaccination in pediatric kidney and liver transplantation. Pediatr Transplant 14:41–47
Zamora I, Simon JM, Da Silva ME, Piqueras AI (1994) Attenuated varicella virus vaccine in children with renal transplants. Pediatr Nephrol 8:190–192
Weinberg A, Horslen SP, Kaufman SS, Jesser R, Devoll-Zabrocki A, Fleckten BL, Kochanowicz S, Seipel KR, Levin MJ (2006) Safety and immunogenicity of varicella-zoster virus vaccine in pediatric liver and intestine transplant recipients. Am J Transplant 6:565–568
Kano H, Mizuta K, Sakakihara Y, Kato H, Miki Y, Shibuya N, Saito M, Norita M, Kawarasaki H, Igarashi T, Hashizume K, Iwata T (2002) Efficacy and safety of immunization for pre- and post-liver transplant children. Transplantation 74:543–550
Olson AD, Shope TC, Flynn JT (2001) Pretransplant varicella vaccination is cost-effective in pediatric renal transplantation. Pediatr Transplant 5:44–50
Fadrowski JJ, Furth SL (2004) Varicella zoster virus: vaccination and implications in children with renal failure. Expert Rev Vaccines 3:291–298
Kitai IC, King S, Gafni A (1993) An economic-evaluation of varicella vaccine for pediatric liver and kidney-transplant recipients. Clin Infect Dis 17:441–447
Author information
Authors and Affiliations
Corresponding author
Additional information
Lothar Bernd Zimmerhackl is deceased.
Rights and permissions
About this article
Cite this article
Prelog, M., Schönlaub, J. & Zimmerhackl, L.B. Aciclovir and Varicella-zoster-immunoglobulin in solid-organ transplant recipients. Pediatr Nephrol 26, 663–673 (2011). https://doi.org/10.1007/s00467-010-1666-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-010-1666-z